1. Home
  2. GDEV vs CABA Comparison

GDEV vs CABA Comparison

Compare GDEV & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GDEV Inc.

GDEV

GDEV Inc.

HOLD

Current Price

$14.00

Market Cap

289.9M

Sector

Technology

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$2.96

Market Cap

319.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GDEV
CABA
Founded
2009
2017
Country
Cyprus
United States
Employees
589
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
289.9M
319.6M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
GDEV
CABA
Price
$14.00
$2.96
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$14.57
AVG Volume (30 Days)
784.0
2.2M
Earning Date
04-06-2026
03-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.89
N/A
P/E Ratio
$5.19
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.60
$0.99
52 Week High
$42.20
$3.78

Technical Indicators

Market Signals
Indicator
GDEV
CABA
Relative Strength Index (RSI) 41.51 46.30
Support Level $12.49 $2.11
Resistance Level $16.62 $3.34
Average True Range (ATR) 0.43 0.21
MACD -0.09 -0.06
Stochastic Oscillator 5.21 17.50

Price Performance

Historical Comparison
GDEV
CABA

About GDEV GDEV Inc.

GDEV Inc is a gaming and entertainment holding company that oversees a portfolio of studios focused on developing and publishing live-service games across a range of platforms and genres. Its portfolio includes studios specializing in mobile, browser, and PC games, as well as captivating IPs spanning various genres.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: